Molly M Jeffery
Biographic Data
| ID | 5538422 |
|---|---|
| NAME | Molly M Jeffery |
| GIVEN NAMES | Molly M |
| FAMILY NAME | Jeffery |
| SIGNATURE | JEFFERY M M |
| AFFILIATIONS | Department of Health Sciences Research, Mayo Clinic, Rochester, MN |
| ORCID | 0000-0003-3854-6810 |
| VERIFIED | Yes |
| TOTAL WORKS | 5 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 5 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2012 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 0 |
Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs
In this cohort study, new 340B participation was associated with statistically significant higher oncological drug episode spending compared with nonparticipants after changes in 340B inclusion rules in 2010. These findings raise questions about unintended consequences of the 340B program on drug spending from the commercially insured population
Uptake of Biosimilar Among Privately Insured Patients Undergoing Infliximab Treatment
BACKGROUND: Recent literature has found rapid uptake of short-acting filgrastim biosimilars but slower uptake of other biosimilars, such as infliximab, in both Medicare and privately insured enrollees. OBJECTIVES: To describe patient, provider, and health plan characteristics associated with a switch to biosimilar among existing infliximab patients. RESEARCH DESIGN: We constructed a retrospective panel dataset of patients undergoing active inflix…
Changes in all-cause and cause-specific mortality during the first year of the Covid-19 pandemic in Minnesota
The COVID-19 pandemic was associated with a 17% increase in the death rate in Minnesota relative to 2018-2019, driven by both COVID-19 and non-COVID-19 causes. As the COVID-19 pandemic enters its third year, it is imperative to examine and address the factors contributing to excess mortality in the short-term and monitor for additional morbidity and mortality in the years to come
Response to Propoxyphene Market Withdrawal
OBJECTIVE: Experts cautioned that patients affected by the November 2010 withdrawal of the opioid analgesic propoxyphene might receive riskier prescriptions. To explore this, we compared drug receipts and outcomes among propoxyphene users before and aftermarket withdrawal. STUDY DESIGN: Using OptumLabs data, we studied 3 populations: commercial, Medicare Advantage (MA) aged (age 65+ y) and MA disabled (age below 65 y) enrollees. The exposed enrol…
The Effectiveness of a Health Promotion Program After 3 Years
BACKGROUND: Health promotion programs for the workplace are often sold to employers with the promise that they will pay for themselves with lowered health care expenditures and reduced absenteeism. In a recent review of the literature, it was noted that analysts often caution not to expect a positive return on investment until the third year of operation. OBJECTIVE: This study investigates whether a positive return on investment was generated in …
No prominent works on this page.
The Effectiveness of a Health Promotion Program After 3 Years
BACKGROUND: Health promotion programs for the workplace are often sold to employers with the promise that they will pay for themselves with lowered health care expenditures and reduced absenteeism. In a recent review of the literature, it was noted that analysts often caution not to expect a positive return on investment until the third year of operation. OBJECTIVE: This study investigates whether a positive return on investment was generated in …
Response to Propoxyphene Market Withdrawal
OBJECTIVE: Experts cautioned that patients affected by the November 2010 withdrawal of the opioid analgesic propoxyphene might receive riskier prescriptions. To explore this, we compared drug receipts and outcomes among propoxyphene users before and aftermarket withdrawal. STUDY DESIGN: Using OptumLabs data, we studied 3 populations: commercial, Medicare Advantage (MA) aged (age 65+ y) and MA disabled (age below 65 y) enrollees. The exposed enrol…
Changes in all-cause and cause-specific mortality during the first year of the Covid-19 pandemic in Minnesota
The COVID-19 pandemic was associated with a 17% increase in the death rate in Minnesota relative to 2018-2019, driven by both COVID-19 and non-COVID-19 causes. As the COVID-19 pandemic enters its third year, it is imperative to examine and address the factors contributing to excess mortality in the short-term and monitor for additional morbidity and mortality in the years to come
Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs
In this cohort study, new 340B participation was associated with statistically significant higher oncological drug episode spending compared with nonparticipants after changes in 340B inclusion rules in 2010. These findings raise questions about unintended consequences of the 340B program on drug spending from the commercially insured population
Uptake of Biosimilar Among Privately Insured Patients Undergoing Infliximab Treatment
BACKGROUND: Recent literature has found rapid uptake of short-acting filgrastim biosimilars but slower uptake of other biosimilars, such as infliximab, in both Medicare and privately insured enrollees. OBJECTIVES: To describe patient, provider, and health plan characteristics associated with a switch to biosimilar among existing infliximab patients. RESEARCH DESIGN: We constructed a retrospective panel dataset of patients undergoing active inflix…
Medicine (5 works) · Internal Medicine (4 works) · Actuarial science (2 works) · Business (2 works) · Economic growth (2 works) · Economics (2 works) · Health care (2 works) · Internal Medicine (2 works) · Pharmaceutical Economics and Policy (2 works) · Pharmacology (2 works)